A Reliable Research Partner in Life Science and Medicine

Recombinant Human Interleukin-17A/IL-17A Protein

Catalog Number: PKSH032620

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Human

Source E.coli-derived Human Interleukin-17A;IL-17A protein Ile20-Ala155, with an C-terminal

His

Calculated MW16.5 kDaObserved MW17 kDaAccessionQ16552

Bio-activity Measure by its ability to induce IL-6 secretion in 3T3 cells. The ED_{50} for this effect is

<6 ng/mL.

Properties

Purity > 98 % as determined by reducing SDS-PAGE.

Endotoxin < 0.01 EU per μ g of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

Shipping This product is provided as lyophilized powder which is shipped with ice packs.

Formulation Lyophilized from sterile PBS,pH 8.0.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

Reconstitution Please refer to the printed manual for detailed information.

Data



> 98 % as determined by reducing SDS-PAGE.

Background

Elabscience®

Elabscience Biotechnology Co., Ltd.

A Reliable Research Partner in Life Science and Medicine

Interleukin-17 is a potent pro-inflammatory cytokine produced by activated memory T cells. There are at least six members of the IL-17 family in humans and in mice. As IL-17 shares properties with IL-1 and TNF-alpha; it may induce joint inflammation and bone and cartilage destruction. This cytokine is found in synovial fluids of patients with rheumatoid arthritis; and produced by rheumatoid arthritis synovium. It increases IL-6 production; induces collagen degradation and decreases collagen synthesis by synovium and cartilage and proteoglycan synthesis in cartilage. IL-17 is also able to increase bone destruction and reduce its formation. Blocking of interleukin-17 with specific inhibitors provides a protective inhibition of cartilage and bone degradation.